Spyre's SPY003 meets primary endpoint in Phase 2 UC trial
Go back to Spyre's SPY003 meets primary endpoint in Phase 2 UC trial| (NASDAQ: SYRE) | Delayed: 94.55 +3.15 (3.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $91.40 | 52 Week High | $ | |||
| Open | $92.78 | 52 Week Low | $ | |||
| Day High | $95.17 | P/E | N/A | |||
| Day Low | $92.32 | EPS | $ | |||
| Volume | 242,777 | |||||



